April 8th 2020
Surya Singh, MD, discussed dynamics that affect biosimilar uptake on the medical benefits side and how that differs from the pharmacy benefits side at the recent FDA/Federal Trade Commission workshop on anticompetitive practices.
April 7th 2020
Soumi Saha, PharmD, JD, senior director of advocacy at Premier, Inc, discusses drug shortages caused by coronavirus disease (COVID-19) and policy recommendations that could fix the problem.
April 2nd 2020
Christine Simmon discussed the Purple Book and how it will affect biosimilar makers and illuminate patent hurdles at the recent FDA/Federal Trade Commission workshop on anticompetitive practices.
March 30th 2020
Matt Harman talks about what employers can do to help promote biosimilar adoption in the United States, during the World Biosimilar Congress USA 2020 at the Festival of Biologics USA in San Diego, California.
March 26th 2020
Matt Harman talks about employer interest in biosimilar promotion and how the FDA's new biologics pathway change will affect interest levels, during the World Biosimilar Congress USA 2020 at the Festival of Biologics USA in San Diego, California.
March 24th 2020
Wayne Winegarden, PhD, talked about the issues and benefits of the FDA's switch to a biologics regulatory pathway for certain products, especially insulin, during the World Biosimilar Congress USA 2020 at the Festival of Biologics USA in San Diego, California.
March 17th 2020
Sheila Frame, the vice president of marketing, market access, and patient services at Sandoz, discusses US biosimilar policies in development and the impact they will have on the market at the World Biosimilar Congress 2020 at the Festival of Biologics USA in San Diego, California.
March 13th 2020
Wayne Winegarden, PhD discusses the potential savings inherent in biosimilars at the World Biosimilar Congress 2020 at the Festival of Biologics USA in San Diego, California.
March 2nd 2020
Gillian Woollett, MA, DPhil, senior vice president, Avalere Health, explains the importance of consistency in applying critical product quality attributes.
February 18th 2020
Using biosimilars to reduce costs of cancer care is necessary, says Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at MD Anderson Cancer Center.
